Geoff Houlton

A drug that corrects complications that occur with the prostrate and prostrate cancer. Entering phase 2 clinical trials, has large market opportunities. Have done safety studies. In good shape regarding their cash position.

Has raised capital. Produces a hand held company to assist primary care physicians, to help electronic prescribing. It doesn’t cost the physician anything. The company is doing very well.

Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.

A very interesting company. Has an animal health product, human health products focused on bladder cancer and a vaccine for cattle. Likes the company, has existing products (short-term revenue stream) and has future opportunity and a potential blockbuster product. A significant opportunity.

Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.

Focuses on providing software for doctors, directed at Primary physicians. Have lots of new products coming through. Great opportunity.

Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.